Biosecure Act Fails to be Enacted

December 31, 2024

BIOSECURE Act Faces Hurdles and Uncertainty in 2025

The Biosecure Act missed its expected ride through the U.S. Congress when the Senate failed to include it in the National Defense Authorization Act. However, it may not be the end of the road for the bill that would prohibit direct or indirect U.S. government contracts with listed Chinese “biotechnology companies of concern.”


The U.S. House of Representatives had previously passed HR 8333, commonly known as the BIOSECURE Act by 306-81, far exceeding the two thirds vote required to pass. The text of this bill was unamended from the version approved by the House Committee on Oversight and Accountability in May (the “House bill”). The House also chose not to include the bill in its version of the NDAA.


There was a slim chance that the bill could pass the Congress this year by hitching a ride with a CR to close the session, but it wasn’t meant to be.


The path to law for the BIOSECURE Act is even more uncertain heading into 2025.


Previously as ranking member, Sen. Paul of Kentucky cast the sole objection vote against BIOSECURE when it passed the committee in March. At that time, Paul voiced concerns over hidden anti-competition motivations behind the bill, as well as its ramifications of potential disruptions to biopharma supply chain. As Republicans take control of the Senate, Sen. Paul of Kentucky is slated to chair the Senate Homeland Security and Governmental Affairs Committee and may prove to be an obstacle to BIOSECURE once again.


MichBio will keep close tabs on any BIOSECURE legislation with its two key legislators – U.S. Rep. Moolenaar in the House who heads up the China Select Committee and Sen. Peters who was the lead sponsor of the Senate bill.

RECENT ARTICLES

March 28, 2025
Secure Your Spot at The MedTech Conference 2025 with MichBio!
March 28, 2025
Propelling Innovation in CNS Biotherapeutics
March 28, 2025
Dexter Biometry is a contract bioinformatics service, specializing in data analysis, data visualization dashboards and reports, pipeline automation and other digital services for biotech, pharma and academic science. Founded in 2024 to help scientists lacking adequate informatics staff quickly solve a wide variety of data problems, they have leveraged decades of scientific experience to help clients across the country and across scientific disciplines. They have provided cost-effective client solution at a variety of scales, from assistance with manuscript preparation all the way to cloud deployments of containerized pipelines. Early clients have primarily focused on genomics, proteomics and immune oncology, however Dexter Biometry is currently expanding their services into other fields such as virology and agricultural genomics. Built on client relationships in San Diego and Baltimore, Dexter Biometry is looking to build relationships with clients closer to their home in Dexter, MI, where remote services can be augmented with on-site help when needed. Visit their website to learn more: https://dexterbiometry.com/ 
Share by: